Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TA103 in tinea pedis
NCT04883593Phase 1Completed
- Start
- Sep 2020
- Primary completion
- Feb 2021
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in tinea pedis comparing TA103 with Placebo Control (2 arms). Primary endpoint: Proportion of subjects with complete cure at 6 weeks. Started Sep 2020; status: completed.
02
Drugs
TA103
03
Conditions
tinea pedis
Beyond the preview
Go deeper on NCT04883593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04883593.